Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Q4 2023 Earnings Presentation
23 slides from Avita Medical's earnings presentation, Feb 28, 2024
Slide 1: Accelerating Our Growth Profile
NASDAQ: RCEL ASX: AVH For personal use only Accelerating Our Growth Profile Investor Presentation February 22, 2024
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers 2024.Q4 v9 Certain statements in this presentation and the accompanying oral commentary are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts
Slide 3: Leadership
Leadership For personal use only Donna Shiroma Terry Bromley Debbie Garner Jim Corbett David O’Toole SVP, Global Marketing & Chief Executive Officer* Chief Financial Officer* General Counsel* SVP, Global Sales Strategy 30+ Years of Experience 30+ Years of Experience 20+ Years of Experience 20+ Years
Slide 4: Investment Overview
Investment Overview > Commercial-stage company focused on regenerative medicine to transform the standard of care in wound care management and skin restoration with innovative technology For personal use only > Current U.S. FDA-Approved Indications for RECELL: • Thermal burn wounds and full-thicknes
Slide 5: RECELL Platform. Multiple Indications.
RECELL Platform. Multiple Indications. For personal use only Approved U.S. INDICATIONS 2022 2023 2024 2025 Outpatient Code Ease of Use Device BURNS Japan: Approval, RECELL GO Device Reimbursement, Launch Submission: June 30 Expect RECELL GO FDA Approval*: May 30 Expect RECELL GO Device Launch*: May
Slide 6: Technology Overview
For personal use only Technology Overview P6
Slide 7: What is RECELL?
What is RECELL? T R E AT M E N T US I N G R EC E L L R EC E L L enables For personal use only Deliver: autologous suspension sprayed regeneration of healthy onto treatment areas of patient skin 3 2 Prepare: at patient’s bedside, process skin and disaggregate cells with RECELL to produce regenerative
Slide 8: RECELL Device Evolution
RECELL Device Evolution For personal use only R EC E L L G O D U R A B L E R EC E L L G O D I S P O SA B L E C A RT R I D G E FIRST GENERATION DEVICE RECELL GO DEVICE • Fewer steps and streamlined • More controlled cell disaggregation and workflow, allowing for faster set up filtration • Reduces tim
Slide 9: Commercial Overview
For personal use only Commercial Overview P9
Slide 10: RECELL: Full-Thickness Skin Defect Launch
RECELL: Full-Thickness Skin Defect Launch F TS D U T I L I Z ES I N - PAT I E NT R E I M B U R S E M E N T: For personal use only • Same DRG code as burns; effective immediately F TS D U T I L I Z ES O U T- PAT I E N T T RAN S I T I O N AL PASS-T H RO U GH CO D E (T PTC ): • Same code as burns; effe
Slide 11: Synergies Between Burns and Full-Thickness Skin Defects
Synergies Between Burns and Full-Thickness Skin Defects FULL-THICKNESS SKIN DEFECTS INDICATION MEANINGFULLY BROADENS BUSINESS For personal use only Sales Team Will Target 800+ Trauma Centers & Burn Centers Over Next 3 to 5 Years ~127,000 Targeted Acute Wound 25,000 Targeted Burn Procedures + Procedu
Slide 12: RECELL: Market Sizing for Burn and Full-Thickness Skin Defects
RECELL: Market Sizing for Burn and Full-Thickness Skin Defects Market Size Additional Market Opportunity Prior to FDA Approval 1 with FDA Approved Expanded Indication of FTSD1 For personal use only Traumatic Wounds Traumatic Wounds Surgical Wounds • Degloving (Open Wounds) 99,000 • Gun Shot Wounds 1
Slide 13: Global Commercialization Strategy for RECELL
Global Commercialization Strategy for RECELL FOCUSED MARKET For personal use only • Australia • European Union • Japan STRATEGY • Plan to expand exclusively through third-party distribution partners UPDATE • In November 2023, engaged first European distribution partner, PolyMedics Innovations, to le
Slide 14: U.S. Commercialization Strategy for PermeaDerm
U.S. Commercialization Strategy for PermeaDerm On January 10, 2024, AVITA Medical signed distribution agreement with Stedical Scientific to commercialize PermeaDerm ® Biosynthetic Wound Matrix For personal use only PERMEADERM OVERVIEW • Biosynthetic wound dressing applied for the treatment and heali
Slide 15: Long-term Horizon: Vitiligo Opportunity
Long-term Horizon: Vitiligo Opportunity R EC E I V E D F DA A P P ROVA L I N J U N E 2023, W I T H ST U DY R E S U LTS : Patient from a prior study at six-months > • Primary endpoint: proportion of study sites achieving ≥80% re- RECELL-treated area was 100% For personal use only pigmentation for REC
Slide 16: Financials
For personal use only Financials P 16
Slide 17: Average Selling Price
Average Selling Price FDA APPROVED DEVICES For personal use only • 1920: $6,500 • RECELL Ease of Use: $6,500 PENDING FDA APPROVAL • RECELL GO: • Durable device: to provide at no cost • Disposable cartridge: $6,500 R EC E L L G O D I S P O SA B L E C A RT R I D G E R EC E L L G O D U R A B L E P 17
Slide 18: Financial Update
Financial Update 2023 F I N A N C I AL H I GH L I GH TS For personal use only Commercial revenue, excluding BARDA revenue: • Q4 2023: $14.1 million; increase of ~50% compared to same period in 2022 • 2023: $49.8 million; increase of ~46% compared to full-year 2022 Gross profit margin: • 2023: ~84.5%
Slide 19: Financial Overview
Financial Overview STRONG COMMERCIAL GROWTH For personal use only Full-Year Three-Months Ended Ended 16,000 (USD in $000s) Mar 31, 2023 Jun 30, 2023 Sep 30, 2023 Dec 31, 2023 2023 14,000 Commercial Sales $10,458 $11,686 $13,547 $14, 102 $49,775 U.S. Commercial Sales 12,000 Total Revenue $10,550 $11,
Slide 20: Summary
For personal use only Summary P 20
Slide 21: 2023: A Year of Inflection
2023: A Year of Inflection > BURNS • Continued to penetrate, adopt, and grow in core burn centers U.S. MARKET FOR RECELL • For personal use only Utilization expanded as sales force targeted remaining 30% of market sitting outside FTSD and vitiligo greatly expand opportunity of burn centers Burn Pati
Slide 22: Looking Ahead: 2024 Priorities
Looking Ahead: 2024 Priorities > CO M M E RC I A L E X PAN S I O N For personal use only • Expanding our field sales organization from 70 to 108 professionals in Q1 2024 > P RO D U CT P O RT FO L I O E X PAN S I O N • Integrating PermeaDerm into our selling portfolio; plan to launch in March 2024 •
Slide 23: For personal use only
For personal use only